144 related articles for article (PubMed ID: 38085554)
1. Another step toward frontline BTK inhibitor therapy in MCL.
Hanel W; Epperla N
Blood Adv; 2023 Dec; 7(23):7358-7360. PubMed ID: 38085554
[No Abstract] [Full Text] [Related]
2. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P
Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H
Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613
[TBL] [Abstract][Full Text] [Related]
4. Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement.
Zinzani PL; Martelli M; Ferrero S; Gentile M; Laurenti L; Romana Mauro F; Sportoletti P; Tedeschi A; Varettoni M; Visco C
Hematol Oncol; 2022 Oct; 40(4):518-527. PubMed ID: 35247223
[TBL] [Abstract][Full Text] [Related]
5. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
6. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
Jiang VC; Liu Y; Lian J; Huang S; Jordan A; Cai Q; Lin R; Yan F; McIntosh J; Li Y; Che Y; Chen Z; Vargas J; Badillo M; Bigcal JN; Lee HH; Wang W; Yao Y; Nie L; Flowers CR; Wang M
J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36719376
[TBL] [Abstract][Full Text] [Related]
7. The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma.
Li J; Yu H; Wang X; Ye Y; Fang W; Ding N; Mi L; Ping L; Wang X; Song Y; Zhu J
Cancer Control; 2022; 29():10732748221143881. PubMed ID: 36519740
[TBL] [Abstract][Full Text] [Related]
8. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
Zhang Q; Wang HY; Liu X; Nunez-Cruz S; Jillab M; Melnikov O; Nath K; Glickson J; Wasik MA
J Immunol; 2019 Oct; 203(8):2043-2048. PubMed ID: 31534006
[TBL] [Abstract][Full Text] [Related]
9. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.
Weaver AN; Jimeno A
Drugs Today (Barc); 2020 Aug; 56(8):531-539. PubMed ID: 33025948
[TBL] [Abstract][Full Text] [Related]
10. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Rule S; Chen RW
Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
[TBL] [Abstract][Full Text] [Related]
11. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
[TBL] [Abstract][Full Text] [Related]
12. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Dreyling M; Tam CS; Wang M; Smith SD; Ladetto M; Huang H; Novotny W; Co M; Romano A; Holmgren E; Huang J; Gouill SL
Future Oncol; 2021 Jan; 17(3):255-262. PubMed ID: 32985902
[TBL] [Abstract][Full Text] [Related]
13. [Pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory (R/R) Mantle Cell Lymphoma].
Fileni C; Sarkozy C
Bull Cancer; 2023 Oct; 110(10):988-990. PubMed ID: 37658026
[No Abstract] [Full Text] [Related]
14. Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
Yan X; Zhou Y; Huang S; Li X; Yu M; Huang J; Wang J; Ma Z; Jin J; Pan J; Li C; Li F; Jin J
J Cancer Res Clin Oncol; 2018 Apr; 144(4):697-706. PubMed ID: 29392403
[TBL] [Abstract][Full Text] [Related]
15. Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?
McCulloch R
Br J Haematol; 2023 Aug; 202(4):718-719. PubMed ID: 37188352
[TBL] [Abstract][Full Text] [Related]
16. Targeting protein kinase C in mantle cell lymphoma.
Rauert-Wunderlich H; Rudelius M; Ott G; Rosenwald A
Br J Haematol; 2016 May; 173(3):394-403. PubMed ID: 26914495
[TBL] [Abstract][Full Text] [Related]
17. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Bond DA; Maddocks KJ
Hematol Oncol Clin North Am; 2020 Oct; 34(5):903-921. PubMed ID: 32861286
[TBL] [Abstract][Full Text] [Related]
18. Zanubrutinib: First Approval.
Syed YY
Drugs; 2020 Jan; 80(1):91-97. PubMed ID: 31933167
[TBL] [Abstract][Full Text] [Related]
19. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
[TBL] [Abstract][Full Text] [Related]
20. MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.
Wu X; Nowakowski KE; Abeykoon JP; Manske M; Stenson MJ; Timm MM; Hanson CA; Van Dyke DL; Dasari S; Witzig TE
Eur J Haematol; 2021 Oct; 107(4):458-465. PubMed ID: 34214199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]